A double recombinant adenovirus expressing the costimulatory molecule B7-1 (Murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model

Journal of Immunology

Volumn 160, Issue 5, 1998, Pages 2531-2538

  Emtage, Peter C R ^a   Wan, Yonghong ^a   Bramson, Jonathan L ^a   Graham, Frank L ^a   Gauldie, Jack ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b Department of Pathology ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; VIRUS RECOMBINANT;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; ANTIGENS, CD80; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR ESCAPE;

EID: 0032032264     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Boon, T., J. C. Cerottini, B. Eynde, P. Bruggen, and A. V. Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337.
2. Houghton, A. N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1.
3. Pardoll, D. M. 1994. Tumour antigens: a new look for the 1990s. Nature 369:357.
4. Germain, R. N. 1994. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76:287.
5. Freeman, G. J., A. S. Freedman, J. M. Segil, G. Lee, J. F. Whitman, and L. M. Nadler. 1989. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143:2714.
6. Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, L. J. Zhou, M. White, J. D. Fingeroth, J. G. Gribben, and L. M. Nadler. 1991. Structure, expression and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174:625.
7. Lindsley, P. S., E. A. Clark, and J. A. Ledbetter. 1990. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Natl. Acad. Sci. USA 87:5031.
8. Brunet, F.-J., F. Denizot, M.-F. Luciani, M. Roux-Dosseto, M. Suzan, M.-G. Mattei, and P. Golstein. 1987. A new member of the immunoglobulin superfamily-CTLA-4. Nature 328:267.
9. Freedman, A. S., G. Freeman, J. C. Horowitz, J. Daly, and L. M. Nadler. 1987. B7, a B-cell-restricted antigen that identifies preactivated B cells. J. Immunol. 139:3260.
10. Yokochi, T., R. D. Holly, and E. A. Clark. 1982. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J. Immunol. 128:823.
11. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
12. June, C. H., J. A. Ledbetter, P. S. Linsley, and C. B. Thompson. 1990. Role of the CD28 receptor in T-cell activation. Immunol. Today 11:211.
13. Linsley, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191.
14. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065.
15. + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med. 177:1791.
16. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. H. Phillips, L. L. Lanier, and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76.
17. Linsley, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191.
18. Topalian, S. L., D. Solomon, and S. A. Rosenberg. 1989. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142:3714.
19. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, J. G. Gribben, J. W. Ng, J. Kim, J. M. Goldberg, K. Hathcock, and G. Laszlo. 1993a. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178:2185.
20. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. A. Restivo, Jr., L. A. Lombard, G. S. Gray, and L. M. Nadler. 1993b. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909.
21. Chen, L., S. Ashe, W. A. Brady, I. Hellström, K. E. Hellström, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
22. + T cells by B7-transfected melanoma cells. Science 259:368.
23. Yang, G., K. E. Hellström, I. Hellström, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
24. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153:421.
25. Ramarathinam, L., M. Castle, Y. Wu, and Y. Liu. 1994. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 179:1205.
26. Townsend, S. E., F. W. Su, J. M. Atherton, and J. P. Allison. 1994. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:6477.
27. La Motte, R. N., M. A. Rubin, E. Barr, J. M. Leiden, J. A. Bluestone, and M. B. Mokyr. 1996. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol. Immunother. 42:161.
28. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248:1349.
29. Essery, G., M. Feldmann, and J. R. Lamb. 1988. Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. Immunology 64:413.
30. Addison, C. L., T. Braciak, R. Ralston, W. J. Muller, J. Gauldie, and F. L. Graham. 1995. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. USA 92:8522.
31. Herlyn, M. 1990. Human melanoma: development and progression. Cancer Metastasis Rev. 9:101.
32. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59.
33. Graham, F. L. 1987. Growth of 293 cells in suspension culture. J. Gen. Virol. 68:937.
34. Kunsken, D. S. 1996. Construction and characterization of an adenovirus vector containing a bicistronic IL-12 expression cassette. Masters Thesis, McMaster University, Hamilton, Ontario, Canada.
35. Bett, A. J., W. Haddara, L. Prevec, and F. L. Graham. 1994. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA 91:8802.
36. Guy, C. T., R. D. Cardiff, and W. J. Muller. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12:954.
37. Jang, S. K., H. G. Krausslich, M. J. Nicklin, G. M. Duke, A. C. Palmenberg, and E. Wimmer. 1988. A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. 62:2636.
38. Bramson, J. L., M. Hitt, C. L. Addison, W. J. Muller, J. Gauldie, and F. L. Graham. 1996. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther. 7:1995.
39. Rosenberg, S. A., M. T. Lotze, J. C. Yang, P. M. Aebersold, W. M. Linehan, C. A. Seipp, and D. E. White. 1989. Experience with the use of high-dose interleukin-2 in the treatment of 652 patients. Ann. Surg. 210:474.
40. Addison, C. L., J. Gauldie, W. J. Muller, and F. L. Graham. 1995. An adenovirus vector expressing interleukin-4 modulates tumorigenicity and induces tumor regression in a murine breast cancer model. Int. J. Oncol. 7:1253.
41. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, C. Simpson, C. Carter, S. Bock, D. Schwartzentruber, J. P. Wei, and D. E. White. 1988. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319:1676.
42. Rosenberg, S. A., M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, S. E. Ettinghausen, Y. L. Matory, J. M. Skibbery, E. Shiloni, J. T. Vetto, C. A. Seipp, C. Simpson, and C. M. Reichert. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with cancer. N. Engl. J. Med. 313:1485.
43. Friedmann, T. 1989. Progress towards human gene therapy. Science 244:1275.
44. Mattijssen, V., P. H. De Mulder, J. H. Schomagel, J. Verweij, P. Van Den Broek, A. Galazka, S. Roy, and D. J. Ruiter. 1991. Clinical and immunopathological results of phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced non pretreated head and neck squamous cell carcinoma. J. Immunother. 10:63.
45. Rosenberg, S. A., P. Aebersold, K. Cornetta, A. Kasid, R. Morgan, R. Moen, E. M. Karson, M. T. Lotze, J. C. Yang, S. L. Topalian, M. J. Merino, K. Culver, D. Miller, R. M. Blaese, and W. F. Anderson. 1990. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323:570.
46. Fearon, E. R., D. Pardoll, T. Itaya, P. Golumbek, H. I. Levitsky, J. W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of antitumor response. Cell 60:397.
47. Ley, V., C. Roth, P. Langlade-Demoyen, E. L. Larssonsiard, and P. Kourilsky. 1990. A novel approach to the induction of specific cytotoxic T cells in vivo. Res. Immunol. 141:855.
48. Gransbacher, B., K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilbao. 1990. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172:1217.
49. + T cells against the wild-type tumor: correlation with antigen presentation capability. J. Exp. Med. 175:1423.
50. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:602.
51. Gimmi, C. D., G. J. Freeman, J. G. Gribben, G. Gray, and L. M. Nadler. 1993. Human T-cell clonal anergy is induced by antigen presentation in the absence of costimulation. Proc. Natl. Acad. Sci. USA 90:6586.
52. Lenschow, D. J., V. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257:789.
53. Boussiotis, V. A., G. J. Freeman, J. Gribben, J. Daley, G. Gray, and L. M. Nadler. 1993. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc. Natl. Acad. Sci. USA 90:11059.
54. Chen, L., P. McGowan, S. Ashe, J. Johnson, Y. Li, I. Hellström, and K. E. Hellström. 1994. Tumor immunogenicity determines the effect of B7 co-stimulation on T cell mediated tumor immunity. J. Exp. Med. 179:523.
55. Matulonis, U., C. Dosiou, C. Lamont, G. J. Freeman, P. Mauch, L. M. Nadler, and J. D. Griffin. 1995. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85:2507.
56. Zitvogel, J., P. D. Robbins, W. J. Storkus, M. R. Clarke, M. J. Maeurer, R. L. Campbell, C. G. Davis, H. Tahara, R. D. Schreiber, and M. T. Lotze. 1996. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol. 26:1335.
57. Putzer, B. M., M. Hitt, W. J. Muller, P. C. R. Emtage, J. Gauldie, and F. L. Graham. 1997. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA 94:10889.
58. Salvadori, S., B. Gansbacher, I. Wernick, S. Tirelli, and K. Zier. 1995. B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum. Gene Ther. 6:1299.
59. Cayeux, S., C. Beck, A. Aicher, B. Dorken, and T. Blankenstein. 1995. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating lymphocytes and are strong vaccines. Eur. J. Immunol. 25:2325.
60. Fallarino, F., A. Ashikari, T. Boon, and T. F. Gajewski. 1997. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12-but not B7-1 transfected tumor cells. Int. Immunol. 9:1259.
61. Cavallo, F., A. Martin-Fontecha, M. Bellone, S. Heltai, E. Gatti, P. Tornaghi, M. Freschi, G. Forni, P. Dellabona, and G. Casorati. 1995. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol. 25:1154.
62. + cells: the role of CD28 costimulation. Scand. J. Immunol. 44:21.
63. Yeh, K. Y., B. A. Pulaski, M. L. Woods, A. J. McAdam, A. A. Gaspari, J. G. Frelinger, and E. M. Lord. 1995. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell. Immunol. 165:217.
64. Chambers, B. J., M. Salcedo, and H. G. Ljunggren. 1996. Triggering of natural killer cells by the costimulatory molecule CD80. Immunity 5:311.